Business Standard

Tuesday, January 14, 2025 | 12:22 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

CureVac stock plunges after mRNA Covid vaccine falls short on protection

The shares plunged more than 52% in German trading, wiping out almost $9.6 billion in market value.

Photo: Bloomberg
Premium

Photo: Bloomberg

Naomi Kresge and Tim Loh | Bloomberg
CureVac NV lost more than half its value after a preliminary analysis of a large study found its Covid-19 vaccine fell short of the high efficacy bar set by other messenger RNA shots.

The shares plunged more than 52% in German trading, wiping out almost $9.6 billion in market value.

The findings, though preliminary, throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. The spread of virus variants muddied the research, but other vaccines have shown they offer protection against those as well.

CureVac plans

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in